Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, MSc, Karin Strecker, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Pavla Kadlecova, PhD, Oleh Zagrijtschuk, MD, Christoph Klade, PhD, Richard Greil, MD

Blood (2014) 124 (21): 3177.

https://doi.org/10.1182/blood.V124.21.3177.3177

Published: 2014

Journal Articles

Leukocyte Count Defines Patients on Risk for Thrombotic Complications with Well Controlled Essential Thrombocythemia- Data from a Patient- Registry

Veronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, Ernst Schloegl, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2014) 124 (21): 1863.

https://doi.org/10.1182/blood.V124.21.1863.1863

Published: 2014

Journal Articles

Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study

Nicole C.C. Them, M.Sc., Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Richard Greil, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Tiina Berg, Klaudia Bagienski, M.Sc., Oleh Zahriychuk, MD, Christoph Klade, PhD, Robert Kralovics, PhD

Blood (2013) 122 (21): 1589.

https://doi.org/10.1182/blood.V122.21.1589.1589

Published: 2013

Journal Articles

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Daniel Lechner, MD, Karin Strecker, MD, Alexander Egle, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Oleh Zahriychuk, MD, MSc, Christoph Klade, PhD, Richard Greil, MD

Blood (2013) 122 (21): 4046.

https://doi.org/10.1182/blood.V122.21.4046.4046

Published: 2013

Journal Articles

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Heinz Gisslinger, MD, PhD, Robert Kralovics, Bettina Gisslinger, Daniel Lechner, MD, Veronika Buxhofer-Ausch, MD, Karin Strecker, MD, Guenther Gastl, MD, Ella Willenbacher, MD, Richard Greil, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ernst Schloegl, MD, Franz-Josef Tarmann, MSc, Michael Zoerer, PhD, Christoph Klade, PhD, Oleh Zahriychuk, MD, Josef Thaler, MD

Blood (2012) 120 (21): 175.

https://doi.org/10.1182/blood.V120.21.175.175

Published: 2012

Journal Articles

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

David Marin, Enrica Morra, MD, Mauricette Michallet, Andrzej Hellmann, MD, Dietger Niederwieser, MD, Ernst Schloegl, MD, Mats Björeman, MD, Kajetana Foryciarz, MD, PhD, Aloysius Y Ho, Kazimierz Kuliczkowski, Gert Ossenkoppele, MD, PhD, Antonella Gozzini, MD, M. Lurdes Guerra, MD, Gregor Verhoef, Ave Mori, MD, Miranda Pans, Marc van Baardewijk, Pharm.D, Juan Luis Steegmann, MD, PhD

Blood (2011) 118 (21): 1689.

https://doi.org/10.1182/blood.V118.21.1689.1689

Published: 2011

Journal Articles

Excellent Stem Cell Mobilization Using Escalated BEACOPP in High-Risk Patients with Hodgkin’s Disease.

Gabriele Kandler, MD, Michael Fillitz, MD, Michaela Moestl, MD, Ernst Schloegl, MD, Regina Reisner, MD, Elisabeth Pittermann-Hoecker, MD, Thomas Noesslinger, MD, Michael Pfeilstoecker, MD Univ.Doz

Blood (2005) 106 (11): 4717.

https://doi.org/10.1182/blood.V106.11.4717.4717

Published: 2005

NARROW

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Leukocyte Count Defines Patients on Risk for Thrombotic Complications with Well Controlled Essential Thrombocythemia- Data from a Patient- Registry

Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

Excellent Stem Cell Mobilization Using Escalated BEACOPP in High-Risk Patients with Hodgkin’s Disease.

Email alerts

ASH Publications

American Society of Hematology

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Leukocyte Count Defines Patients on Risk for Thrombotic Complications with Well Controlled Essential Thrombocythemia- Data from a Patient- Registry

Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera Study

Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

Excellent Stem Cell Mobilization Using Escalated BEACOPP in High-Risk Patients with Hodgkin’s Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only